

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: July 7, 2008

Signature: /David A. Gass #38,153/  
David A. Gass

Docket No.: 30847/2048-004  
(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
Anna Helgadottir

Application No.: 10/829,674

Confirmation No.: 6838

Filed: April 22, 2004

Art Unit: 1634

Title: USE OF 5-LIPOXYGENASE ACTIVATING  
(new) PROTEIN (FLAP) GENE TO ASSESS  
SUSCEPTIBILITY FOR MYOCARDIAL  
INFARCTION

Examiner: J. A. Goldberg

### **AMENDMENT AND REQUEST FOR RECONSIDERATION**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

This amendment is a response to the Office Action dated January 4, 2008, in which pending claims 61, 65 and 66 were rejected under 35 U.S.C. § 112, first paragraph. This response is timely filed with a petition and fee for three months extension of time.

Please amend the above-identified U.S. patent application as follows:

**Amendments to the Specification** begin on page 2 of this paper.

**Amendments to the Claims**, if any, are reflected in the listing of claims that begins on page 3 of this paper.

**Remarks** begin on page 5 of this paper.

This response is accompanied by a Declaration under 37 C.F.R. § 1.132 of Gudmar Thorleifsson, a statistician scientist employed by the assignee, deCODE genetics, which includes documentary exhibits.